These 3 Big Pharma Stocks Are Making Big Plays With AI
Every major biopharma business is staking out territory to take advantage of the artificial intelligence (AI) gold rush. Amid a mishmash of strategies -- like forging partnerships with innovative software companies and biotechs, acquiring promising players, and developing AI capabilities in-house -- no competitor is taking exactly the same approach. It's reasonable to expect that there will be winners and losers, or at least leaders and laggards for now.
With that in mind, let's look at a trio of big pharmas that are making moves to be on top of the pile with regard to squeezing the most value out of AI.
Eli Lilly's (NYSE: LLY) desire to be a leader in using biopharma AI isn't new, but it's driving a huge amount of recent investment activity.
Source Fool.com
